Oncopeptides AB (publ) (ONCO.ST) Stock Analysis & Winston Score

Oncopeptides is a Swedish biotechnology company that develops drugs to treat blood cancers. Its main product is Pepaxti (melflufen), a chemotherapy drug designed for patients with multiple myeloma — a cancer that affects plasma cells in the bone marrow. The company sells to hospitals and oncology clinics, primarily in Europe, after receiving conditional approval from the European Medicines Agency. Oncopeptides earns revenue by selling Pepaxti to healthcare systems and specialty distributors across European markets. The company is small, with a market cap around $400 million, and it operates at a significant loss, spending far more than it earns — reflected in its deeply negative operating margin. Pepaxti previously had U.S. approval withdrawn after a clinical trial raised safety concerns, which remains a major overhang on the business. The key challenge going forward is building commercial traction in Europe while managing cash burn and demonstrating a clear survival benefit that satisfies regulators and prescribing physicians.